What CooperGenomics does

CooperGenomics is a CLIA-certified genetic testing laboratory that provides Preimplantation Genetic Testing for Aneuploidy (PGT-A) to the in vitro fertilization (IVF) industry. Its core product screens IVF embryos for chromosomal abnormalities before transfer, with the stated intent of helping clinicians and patients identify embryos with the highest likelihood of successful implantation and reducing failed transfers and miscarriage risk. The company markets its test at 97-99% accuracy and operates alongside competitor Genomic Prediction in a narrow two-vendor segment of the US fertility testing market.

The company operates as a subsidiary / operating brand under CooperSurgical, a women's health and fertility company with roughly 35 years of industry presence whose corporate headquarters sit at 75 Corporate Drive, Trumbull, Connecticut. Within that umbrella, CooperGenomics integrates with broader ART and reproductive-care product lines and runs patient- and clinician-facing infrastructure including the Genomics Results Portal and Genomics Pay My Bill (USA and Canada) systems. Distribution is conducted as a specialty clinical laboratory: IVF clinics send embryo biopsy samples directly to CooperGenomics, results are returned to ordering physicians, and patients are counseled on transfer decisions. Go-to-market is sales-led, targeting fertility specialists and IVF clinic networks through professional medical channels and industry conferences.

The revenue model is professional-services based, with quote-based pricing typical of clinical laboratory services and no public fee schedule disclosed. CooperGenomics is privately held with no standalone funding or revenue disclosure available, and is currently named as a defendant in a class action lawsuit alongside Genomic Prediction alleging that PGT-A accuracy claims were overstated — a material litigation overhang affecting both market perception and the defensibility of the core technology positioning. Geographic exposure is primarily the United States with ancillary Canadian billing infrastructure, and the company classifies its segmentation as vertical, serving IVF clinics and fertility specialists as institutional customers and IVF patients as end-user decision-makers.

Name

CooperGenomics

Website

https://coopergenomics.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

51–100 employees

Short description

CooperGenomics is a CLIA-certified genetic testing laboratory that provides Preimplantation Genetic Testing for Aneuploidy (PGT-A) to IVF clinics and fertility specialists, operating as a subsidiary of CooperSurgical within the US fertility market.

Ownership category

akta.pro rank

Product category

Reproductive Genetic Testing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)

akta.pro secondary industries

Genetic & Prenatal Testing Laboratories (HLAFAMAH), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)

Keywords

• Preimplantation genetic testing
• IVF embryo screening
• Aneuploidy testing
• Fertility genetic diagnostics
• Embryo chromosomal analysis

Headquarters

HQ city

Livingston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. PGT-A Genetic Testing Services: CooperGenomics generates revenue through providing PGT-A genetic testing services to IVF clinics and fertility practices. The testing is performed on embryos created through IVF, with results used to guide embryo selection decisions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

CooperGenomics provides PGT-A (Preimplantation Genetic Testing for Aneuploidy) genetic testing services for the IVF industry. The company operates as a CLIA-certified laboratory that receives embryo biopsy samples from fertility clinics, performs genetic analysis to screen for chromosomal abnormalities, and returns results to ordering physicians to guide embryo selection and transfer decisions. The service is sold primarily to IVF clinics and fertility specialists.

Product overview

CooperGenomics is a genetic-testing company specializing in preimplantation genetic testing services for the IVF industry. The company's primary offering is PGT-A (Preimplantation Genetic Testing for Aneuploidy), a genetic screening test that analyzes IVF embryos for chromosomal abnormalities. According to news sources, CooperGenomics is one of two companies (alongside Genomic Prediction) facing class action lawsuits regarding the accuracy claims of their PGT-A testing services.

Differentiator

Problem solved

Functional benefit

Products and services

• PGT-A (Preimplantation Genetic Testing for Aneuploidy) Genetic testing service that screens IVF embryos for chromosomal abnormalities (aneuploidy) before implantation. Performed in a CLIA-certified laboratory on biopsy samples submitted by fertility clinics, with results returned to the ordering physician to inform embryo transfer decisions and improve IVF success rates.

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• CooperSurgicalOthersCooperGenomics operates as a subsidiary or brand under CooperSurgical, a women's health and fertility company with nearly 35 years of industry experience. CooperSurgical provides the parent company infrastructure including corporate headquarters in Trumbull, CT, and integrates CooperGenomics services with its broader fertility product portfolio including the Genomics Results Portal and Genomics Pay My Bill systems.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Emerging players

• Sema4 (now GeneDx): Genomic testing company with women's health and reproductive offerings. Competes in adjacent genetic testing categories for similar clinical customers, though with broader genomic profiling emphasis.
• ZyMōt Fertility (acquired by CooperSurgical): Sperm preparation device company recently acquired by CooperGenomics' parent CooperSurgical. Operates in the same fertility clinic workflow, serving IVF labs as an adjacent technology rather than a direct PGT-A competitor.

Broad incumbents

• Myriad Genetics: Genetic testing company with offerings in reproductive health (Prequel NIPT, Foresight carrier screen). Competes with CooperGenomics in reproductive genetic screening but at much broader scale and across multiple specialties.
• Labcorp: Major clinical laboratory offering genetic and reproductive diagnostics including PGT and NIPT. Provides broad laboratory scale and serves similar hospital, clinic, and IVF center customers as CooperGenomics.
• Invitae (now part of Labcorp): Broad genetic testing platform with reproductive and carrier screening offerings. Larger and more diversified than CooperGenomics, serving overlapping fertility clinic customers as part of a wider genetic testing portfolio.
• Quest Diagnostics: Large clinical laboratory with reproductive and prenatal genetic testing offerings. Overlaps with CooperGenomics in serving IVF clinics and OB practices, though as part of a much broader diagnostics portfolio.

Direct peers

• Igenomix: Reproductive genetics laboratory offering PGT-A, PGT-M, and carrier screening services to IVF clinics globally. Competes head-to-head with CooperGenomics in the same clinical workflow and customer segment.
• Genomic Prediction: Direct competitor offering PGT-A and PGT-P (polygenic risk) testing for IVF embryos. Co-named with CooperGenomics in the same class action lawsuit, making it the most directly comparable peer in clinical offering and business model.
• Natera: Genetic testing company with a reproductive health franchise (Empower, Vistara, Spectrum) including PGT and non-invasive prenatal testing. Targets IVF clinics and obstetricians with overlapping genetic testing offerings.
• Progenesis (a CooperSurgical brand): PGT-A and PGT-M provider for IVF clinics. Operates as a sister brand within CooperGenomics' own parent company (CooperSurgical), making it a same-corporate-family peer competing in the same service line.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CooperGenomics